Table 1.

Characteristics of individuals with CLL and HCMBL

	CLL (n = 849)		MBL (n = 381)		Overall (n = 1230)
Female, n, %	258	30.4	138	36.2	396	32.2
Male	591	69.6	243	63.8	834	67.8
Median age (IQR), y	61 (46-76)		67 (52-82)		63 (47-79)
Rai stage 0, n, %	456	54.9
Rai stage 1-4, n, %	374	45.1
Median β2M (IQR), mg/L	2.4 (1.1-3.8)		2.1 (1.4-2.9)		2.3 (1.1-3.6)
IGHV unmutated, n, %	406	51.1	71	24.6	477	44.0
IGHV mutated, n, %	389	48.9	218	75.4	607	56.0
FISH del(11q), n, %	89	10.5	15	3.9	104	8.5
FISH del(13q), n, %	431	50.8	160	42.0	591	48.0
FISH tri(12), n, %	110	13.0	48	12.6	158	12.8
FISH or CNV del(17p), n, %	58	6.8	11	2.9	69	5.6
No TP53 mutations, n, %	748	88.1	348	91.3	1096	89.1
TP53 mutation(s) VAF >10%, n, %	64	7.5	17	4.5	81	6.6
TP53 state, wild-type, n, %	768	90.5	360	94.5	1128	91.7
TP53 state, single-hit, n, %	35	4.1	12	3.1	47	3.8
TP53 state, multihit, n, %	46	5.4	9	2.4	55	4.5
Single-hit TP53 type, n	35		12		47
No TP53 mutation; del(17p), n, %	17	48.6	4	33.3	21	44.7
Single TP53 mutation; normal 17p, n, %	18	51.4	8	66.7	26	55.3
Multihit TP53 type, n	46		9		55
TP53 LOH mutation, n, %	3	6.5	1	11.1	4	7.3
TP53 mutation(s); del(17p), n, %	37	80.4	6	66.7	43	78.2
Multiple TP53 mutations, n, %	6	13.0	2	22.2	8	14.5
Median follow-up, y	5.95		7.27		6.27

CNV, copy number variation.